LRRK2 p.Ile1371Val mutation in a case with neuropathologically confirmed multi-system atrophy

Kelsey Lee, Khanh Dung Nguyen, Chao Sun, Mei Liu, Faria Zafar, Jimmy Saetern, Adrian Flierl, James W. Tetrud, J. William Langston, Dennis W Dickson, Birgitt Schule

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Mutations in the leucine rich repeat kinase 2 (LRRK2) gene are among the most common genetic causes of Lewy body Parkinson's disease (PD). However, LRRK2 mutations can also lead to a variety of pathological phenotypes other than typical PD, including relatively pure nigrostriatal cell loss without alpha-synuclein-positive Lewy bodies or Lewy neurites, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA). The mechanisms behind this remarkable pleomorphic pathology are currently unclear. Objective: To genetically and pathologically characterize a case with a LRRK2, p.Ile1371Val rare variant and pathologically proven MSA. Methods: From the brain donation program at the Parkinson's Institute and Clinical Center, we selected 26 brains with family history and a with clinicopathological diagnosis of PD (n = 20), MSA (n = 4), or PSP (n = 2).We performed neuropathological evaluation, including alpha-synuclein and tau immunohistochemistry and sequenced 188 genes that have been reported as causative for or associated with neurodegenerative diseases. Results: We identified a known LRRK2, p.Ile1371Val genetic variant in a case with clinically diagnosed and pathologically proven MSA. Neuropathology revealed that the olivopontocerebellar system was more affected than the striatonigral system. Conclusions: Our data suggest that genetic variants in the LRRK2 gene can present clinically and neuropathologically as MSA. One other LRRK2 genetic variant (LRRK2, p.Ile2020Thr) has been reported with a neuropathological diagnosis of MSA. Interestingly, the LRRK2 variant (LRRK2, p.Ile1371Val) identified here has been reported previously in a postmortem case with Lewy body PD. Future studies are critical to discover the mechanisms leading to different neurodegenerative trajectories both in neuronal and glial cell populations.

Original languageEnglish (US)
Pages (from-to)93-100
Number of pages8
JournalJournal of Parkinson's Disease
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Leucine
Atrophy
Multiple System Atrophy
Phosphotransferases
Mutation
Parkinson Disease
alpha-Synuclein
Genes
Progressive Supranuclear Palsy
Lewy Bodies
Brain
Neurites
Neuroglia
Neurodegenerative Diseases
Immunohistochemistry
Pathology
Phenotype
Population

Keywords

  • Alpha-synuclein
  • Genetic risk factor
  • Glial cytoplasmic inclusions
  • Leucine-rich repeat kinase 2
  • LRRK2
  • Multiple system atrophy
  • Mutation
  • Neuronal cytoplasmic inclusions
  • Olivopontocerebellar degeneration
  • P.Ile1371Val

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Lee, K., Nguyen, K. D., Sun, C., Liu, M., Zafar, F., Saetern, J., ... Schule, B. (2018). LRRK2 p.Ile1371Val mutation in a case with neuropathologically confirmed multi-system atrophy. Journal of Parkinson's Disease, 8(1), 93-100. https://doi.org/10.3233/JPD-171237

LRRK2 p.Ile1371Val mutation in a case with neuropathologically confirmed multi-system atrophy. / Lee, Kelsey; Nguyen, Khanh Dung; Sun, Chao; Liu, Mei; Zafar, Faria; Saetern, Jimmy; Flierl, Adrian; Tetrud, James W.; Langston, J. William; Dickson, Dennis W; Schule, Birgitt.

In: Journal of Parkinson's Disease, Vol. 8, No. 1, 01.01.2018, p. 93-100.

Research output: Contribution to journalArticle

Lee, K, Nguyen, KD, Sun, C, Liu, M, Zafar, F, Saetern, J, Flierl, A, Tetrud, JW, Langston, JW, Dickson, DW & Schule, B 2018, 'LRRK2 p.Ile1371Val mutation in a case with neuropathologically confirmed multi-system atrophy', Journal of Parkinson's Disease, vol. 8, no. 1, pp. 93-100. https://doi.org/10.3233/JPD-171237
Lee, Kelsey ; Nguyen, Khanh Dung ; Sun, Chao ; Liu, Mei ; Zafar, Faria ; Saetern, Jimmy ; Flierl, Adrian ; Tetrud, James W. ; Langston, J. William ; Dickson, Dennis W ; Schule, Birgitt. / LRRK2 p.Ile1371Val mutation in a case with neuropathologically confirmed multi-system atrophy. In: Journal of Parkinson's Disease. 2018 ; Vol. 8, No. 1. pp. 93-100.
@article{406f2e3ebb194749abfe22bd65a8d15f,
title = "LRRK2 p.Ile1371Val mutation in a case with neuropathologically confirmed multi-system atrophy",
abstract = "Background: Mutations in the leucine rich repeat kinase 2 (LRRK2) gene are among the most common genetic causes of Lewy body Parkinson's disease (PD). However, LRRK2 mutations can also lead to a variety of pathological phenotypes other than typical PD, including relatively pure nigrostriatal cell loss without alpha-synuclein-positive Lewy bodies or Lewy neurites, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA). The mechanisms behind this remarkable pleomorphic pathology are currently unclear. Objective: To genetically and pathologically characterize a case with a LRRK2, p.Ile1371Val rare variant and pathologically proven MSA. Methods: From the brain donation program at the Parkinson's Institute and Clinical Center, we selected 26 brains with family history and a with clinicopathological diagnosis of PD (n = 20), MSA (n = 4), or PSP (n = 2).We performed neuropathological evaluation, including alpha-synuclein and tau immunohistochemistry and sequenced 188 genes that have been reported as causative for or associated with neurodegenerative diseases. Results: We identified a known LRRK2, p.Ile1371Val genetic variant in a case with clinically diagnosed and pathologically proven MSA. Neuropathology revealed that the olivopontocerebellar system was more affected than the striatonigral system. Conclusions: Our data suggest that genetic variants in the LRRK2 gene can present clinically and neuropathologically as MSA. One other LRRK2 genetic variant (LRRK2, p.Ile2020Thr) has been reported with a neuropathological diagnosis of MSA. Interestingly, the LRRK2 variant (LRRK2, p.Ile1371Val) identified here has been reported previously in a postmortem case with Lewy body PD. Future studies are critical to discover the mechanisms leading to different neurodegenerative trajectories both in neuronal and glial cell populations.",
keywords = "Alpha-synuclein, Genetic risk factor, Glial cytoplasmic inclusions, Leucine-rich repeat kinase 2, LRRK2, Multiple system atrophy, Mutation, Neuronal cytoplasmic inclusions, Olivopontocerebellar degeneration, P.Ile1371Val",
author = "Kelsey Lee and Nguyen, {Khanh Dung} and Chao Sun and Mei Liu and Faria Zafar and Jimmy Saetern and Adrian Flierl and Tetrud, {James W.} and Langston, {J. William} and Dickson, {Dennis W} and Birgitt Schule",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JPD-171237",
language = "English (US)",
volume = "8",
pages = "93--100",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - LRRK2 p.Ile1371Val mutation in a case with neuropathologically confirmed multi-system atrophy

AU - Lee, Kelsey

AU - Nguyen, Khanh Dung

AU - Sun, Chao

AU - Liu, Mei

AU - Zafar, Faria

AU - Saetern, Jimmy

AU - Flierl, Adrian

AU - Tetrud, James W.

AU - Langston, J. William

AU - Dickson, Dennis W

AU - Schule, Birgitt

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Mutations in the leucine rich repeat kinase 2 (LRRK2) gene are among the most common genetic causes of Lewy body Parkinson's disease (PD). However, LRRK2 mutations can also lead to a variety of pathological phenotypes other than typical PD, including relatively pure nigrostriatal cell loss without alpha-synuclein-positive Lewy bodies or Lewy neurites, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA). The mechanisms behind this remarkable pleomorphic pathology are currently unclear. Objective: To genetically and pathologically characterize a case with a LRRK2, p.Ile1371Val rare variant and pathologically proven MSA. Methods: From the brain donation program at the Parkinson's Institute and Clinical Center, we selected 26 brains with family history and a with clinicopathological diagnosis of PD (n = 20), MSA (n = 4), or PSP (n = 2).We performed neuropathological evaluation, including alpha-synuclein and tau immunohistochemistry and sequenced 188 genes that have been reported as causative for or associated with neurodegenerative diseases. Results: We identified a known LRRK2, p.Ile1371Val genetic variant in a case with clinically diagnosed and pathologically proven MSA. Neuropathology revealed that the olivopontocerebellar system was more affected than the striatonigral system. Conclusions: Our data suggest that genetic variants in the LRRK2 gene can present clinically and neuropathologically as MSA. One other LRRK2 genetic variant (LRRK2, p.Ile2020Thr) has been reported with a neuropathological diagnosis of MSA. Interestingly, the LRRK2 variant (LRRK2, p.Ile1371Val) identified here has been reported previously in a postmortem case with Lewy body PD. Future studies are critical to discover the mechanisms leading to different neurodegenerative trajectories both in neuronal and glial cell populations.

AB - Background: Mutations in the leucine rich repeat kinase 2 (LRRK2) gene are among the most common genetic causes of Lewy body Parkinson's disease (PD). However, LRRK2 mutations can also lead to a variety of pathological phenotypes other than typical PD, including relatively pure nigrostriatal cell loss without alpha-synuclein-positive Lewy bodies or Lewy neurites, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA). The mechanisms behind this remarkable pleomorphic pathology are currently unclear. Objective: To genetically and pathologically characterize a case with a LRRK2, p.Ile1371Val rare variant and pathologically proven MSA. Methods: From the brain donation program at the Parkinson's Institute and Clinical Center, we selected 26 brains with family history and a with clinicopathological diagnosis of PD (n = 20), MSA (n = 4), or PSP (n = 2).We performed neuropathological evaluation, including alpha-synuclein and tau immunohistochemistry and sequenced 188 genes that have been reported as causative for or associated with neurodegenerative diseases. Results: We identified a known LRRK2, p.Ile1371Val genetic variant in a case with clinically diagnosed and pathologically proven MSA. Neuropathology revealed that the olivopontocerebellar system was more affected than the striatonigral system. Conclusions: Our data suggest that genetic variants in the LRRK2 gene can present clinically and neuropathologically as MSA. One other LRRK2 genetic variant (LRRK2, p.Ile2020Thr) has been reported with a neuropathological diagnosis of MSA. Interestingly, the LRRK2 variant (LRRK2, p.Ile1371Val) identified here has been reported previously in a postmortem case with Lewy body PD. Future studies are critical to discover the mechanisms leading to different neurodegenerative trajectories both in neuronal and glial cell populations.

KW - Alpha-synuclein

KW - Genetic risk factor

KW - Glial cytoplasmic inclusions

KW - Leucine-rich repeat kinase 2

KW - LRRK2

KW - Multiple system atrophy

KW - Mutation

KW - Neuronal cytoplasmic inclusions

KW - Olivopontocerebellar degeneration

KW - P.Ile1371Val

UR - http://www.scopus.com/inward/record.url?scp=85043581610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043581610&partnerID=8YFLogxK

U2 - 10.3233/JPD-171237

DO - 10.3233/JPD-171237

M3 - Article

C2 - 29480226

AN - SCOPUS:85043581610

VL - 8

SP - 93

EP - 100

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 1

ER -